April 15 (Reuters) - Neumora Therapeutics said on Monday the U.S. Food and Drug Administration had placed a clinical hold on early-stage study of its experimental schizophrenia drug. (Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.645 USD | -0.05% | -0.05% | -43.55% |
05-14 | Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression | MT |
05-14 | Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.55% | 1.54B | |
+64.43% | 62.59B | |
-1.70% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.08% | 26.21B | |
-21.78% | 19.09B | |
+4.48% | 13.08B | |
+25.62% | 12.26B | |
+28.34% | 12.05B |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- U.S. FDA places clinical hold on Neumora's schizophrenia drug study